Abstract
<p>An essential step in the drug development process is the accurate detection of drug-target interactions (DTI). The importance of binding affinity values in understanding protein-ligand interactions was previously disregarded, and DTI prediction was only seen as a binary classification problem. In this regard, we introduced the DFDTA-MultiAtt model for predicting the drug target binding affinity in two stages using the structural and sequential information. The first step of the first stage involves retrieving features from sequence data using a bi-directional long short term memory (Bi-LSTM) architecture together with a multi-attention module and dilated convolutional neural network (dilated-CNN) architecture, and the second step features are learnt from structure representation once again using a dilated-CNN. To predict the binding affinity, the second stage uses an ensemble learning model. The proposed model also produces findings with a greater overall accuracy when compared to contemporary state-of-the-art methods. The model generates an enormous +0.006 concordance index (CI) score on the Davis dataset and reduces the mean square error (MSE) by 0.174 on the KIBA dataset.</p>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.